Review: clomipramine is more effective than SSRIs for paediatric obsessive compulsive disorder

March, John S.

doi:10.1136/ebmh.7.2.50

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also beyond the scope of this chapter to review behavioral treatment of OCD, but the reader should be aware that many find cognitive behavior therapy to be as important or more so than drug treatment for this condition [117,118].…”

Section: Effective Monotherapies: Controlled Trialsmentioning

confidence: 99%

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Rapoport

Inoff‐Germain

2007

Handbook of Contemporary Neuropharmacology

View full text Add to dashboard Cite

Obsessive‐compulsive disorder (OCD) is characterized by the presence of unwanted, senseless, intrusive and distressing thoughts, urges and images (obsessions) and/or repetitive behaviors (compulsions). While classified as an anxiety disorder in DSM‐IV, OCD is given a separate chapter here as the clinical phenomenology, drug treatment response, family studies, and brain imaging data support a separate neurobiological classification for this disorder and a distinct neuropharmacologic profile as well. Our current understanding of its underlying neurobiology as well as the state of treatment for OCD is provided through a selective review of OCD‐related (1) brain imaging studies, (2) genetic studies, (3) animal models, (4) psychopharmacology, including immunomodulatory treatment, and (5) experimental non‐pharmacological treatments such as neurosurgery, transcranial magnetic stimulation, and deep brain stimulation.

show abstract

Section: Effective Monotherapies: Controlled Trialsmentioning

confidence: 99%

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Rapoport

Inoff‐Germain

2007

Handbook of Contemporary Neuropharmacology

View full text Add to dashboard Cite

show abstract

Behavioral Disorders of Childhood

Gleason

2012

Textbook of Clinical Pediatrics

View full text Add to dashboard Cite

Pharmacotherapy of anxiety disorders: a critical review

Koen

Stein

2011

Dialogues in Clinical Neuroscience

110

View full text Add to dashboard Cite

Given the enormous contribution of anxiety disorders to the burden of disease, it is key to optimize their prevention and treatment. In this critical review we assess advances in the pharmacotherapy of anxiety disorders, as well as remaining challenges, in recent decades, the field has seen rigorous clinical trial methods to quantify the efficacy and safety of serendipitously discovered agents, more focused development of medications with selective mechanisms of action, and the gradual translation of insights from laboratory research into proof-of-principle clinical trials. On the positive side, a considerable database of studies shows efficacy and relative tolerability of the selective serotonin reuptake inhibitors in the major anxiety disorders, and secondary analyses of such datasets have informed questions such as optimal definition of response and remission, optimal dose and duration, and comparative efficacy of different agents. Significant challenges in the field include barriers to appropriate diagnosis and treatment of anxiety disorders, failure of a significant proportion of patients to respond to first-line pharmacotherapy agents, and a limited database of efficacy or effectiveness studies to guide treatment in such cases.

show abstract

Review: clomipramine is more effective than SSRIs for paediatric obsessive compulsive disorder

Cited by 3 publications

References 4 publications

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Neurobiology and Pharmacotherapy of Obsessive‐Compulsive Disorder

Behavioral Disorders of Childhood

Pharmacotherapy of anxiety disorders: a critical review

Contact Info

Product

Resources

About